Kirn David 4

What Happened
David Kirn, CEO of 4D Molecular Therapeutics (FDMT), was granted a derivative equity award covering 750,000 shares on March 25, 2026. The Form 4 records the transaction as an award/grant (code A) with a reported price of $0.00, indicating a stock option-style grant rather than a cash purchase; the filing extract does not state an exercise/strike price or immediate cash value.

Key Details

• Transaction date: 2026-03-25; Form 4 filed: 2026-03-27 (appears timely; Form 4s are generally due within two business days).
• Award type: derivative stock option award for 750,000 shares (reported at $0.00 in the filing).
• Vesting: vests 1/48th of the shares on each monthly anniversary starting March 25, 2026; fully vested on the fourth anniversary if service continues (see footnote F1).
• Shares owned after transaction: not specified in the provided filing extract.
• Filing notes: footnote F1 specifies the monthly vesting schedule; no 10b5-1 plan, tax withholding, or sale information is indicated.

Context
This is a standard executive compensation grant (unvested options) that gives the CEO the right to acquire shares over time if he remains with the company and (once vested) exercises the options. Such grants are common and do not represent an immediate market purchase or sale. Retail investors should view this as a compensation-related award rather than an insider expressing a near-term buy/sell view.